The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Golcadomide ± rituximab for R/R NHL: Phase I/II trial interim analysis
Jean-Marie Michot, MD, Gustave Roussy Institute, Villejuif, France, discusses the results from an interim analysis of a Phase I/II trial investigating golcadomide (CC-99282) as a monotherapy or in combination with rituximab in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL; NCT03930953). This trial enrolled patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) who had failed two prior lines of therapy, or patients with DLBCL who had failed a single line of therapy and were ineligible for stem cell transplantation (SCT). Dr Michot discusses the tolerability profile of the treatment, and shares early data regarding the efficacy of golcadomide. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
